Market Overview

William Blair Upgrades Vital Therapies Ahead Of September Liver Failure Data

Share:
William Blair Upgrades Vital Therapies Ahead Of September Liver Failure Data
Related VTL
The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares
42 Biggest Movers From Yesterday

Vital Therapies, Inc. (NASDAQ: VTL) has announced the release of data for its liver failure treatment candidate. 

The Analysts

William Blair analyst Y. Katherine Xu upgraded Vital Therapies from Market Perform to Outperform and raised the price target from $10 to $35.

The Thesis

Top-line data from Vital Therapies’ study on the treatment of liver failure is expected to be released in September, Xu said in a Monday note. (See the analyst's track record here.) 

The data on an extracorporeal liver-assist device, or ELAD, versus the standard of care in severe acute alcoholic hepatitis is a key event for Vital, and William Blair raised its estimates accordingly, the analyst said. 

“We note that there are 60,000 sAAH patients annually in the United States and EU, who are associated with about 50-percent mortality. About 60 percent of sAAH patients are younger patients without renal failure or severe coagulopathy, which are part of the main inclusion criteria for VTL-308. Currently, there are no treatment options that provide a survival benefit in this indication, and there is no competition in the clinic addressing this population." 

Xu notes that should this study be successful, ELAD will likely become the standard of care, increasing the peak sales estimate from $850 million to $1.5 billion.

William Blair raised its projection for the treatment's probability of success from 55 percent to 70 percent.

Price Action

Vital Therapies shares were rallying 9.26 percent to $8.85 at the time of publication Monday. 

Related Links:

Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage

The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs

Latest Ratings for VTL

DateFirmActionFromTo
Sep 2018Cantor FitzgeraldDowngradesOverweightNeutral
Sep 2018Raymond JamesDowngradesOutperformMarket Perform
Aug 2018Cantor FitzgeraldInitiates Coverage OnOverweight

View More Analyst Ratings for VTL
View the Latest Analyst Ratings

Posted-In: William Blair Y. Katherine XuBiotech Upgrades Price Target Analyst Ratings Media General Best of Benzinga

 

Related Articles (VTL)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
AAPLWedbushInitiates Coverage On310.0
DHTJP MorganUpgrades0.0
DISBarclaysUpgrades130.0
DXCMGoldman SachsUpgrades125.0
ORLYJP MorganUpgrades398.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Mid-Day Market Update: Crude Oil Up 1.8 %; Technical Communications Shares Spike Higher

Turtle Beach Earnings Preview: Setting Up For A Short Squeeze?